



**Date:** March 6, 2023

**To:** The Honorable Jocelyn Pena-Melnyk, Chair

**From:** Aliyah N. Horton, CAE, Executive Director, MPhA, 240-688-7808

**Cc:** Members, House Government Operations Committee

**Re: FAVORABLE HB 1156 – PHARMACIST–THERAPY MANAGEMENT CONTRACT-FORM**

---

The Maryland Pharmacists Association (MPhA) urges a **FAVORABLE** report for **HB 1156 – Pharmacist-Therapy Management Contract-Form**.

HB 1156 adds flexibility to a requirement for a drug therapy management contract between the pharmacist and patient to be “written, electronic, or oral” – not just written.

This is largely a technical revision to align the drug therapy management contract statute with the growing use of telemedicine by healthcare practitioners and to reduce some of the immediate administrative burden of the written contract that can lead to delays in care.

MPhA consulted with the MedChi on this bill and received a request to modify the language to include that an “oral agreement would be committed to writing within 30 days.” We support this language modification.

MPhA is in alignment with the broader Maryland Pharmacy Coalition position outlined in the oral and written testimony of Dr. Megan Swarthout.